Dec 17, 2024, 23:14
Caterina Sposetti: The impact of a weight loss intervention on key metabolic biomarkers in the phase III BWEL study
Caterina Sposetti, Medical Oncology Fellow at Dana-Farber’s Breast Oncology Center and Dana-Farber Zakim Center, posted on X:
“Dr. Ligibel summarizes the significant impact of a weight loss intervention on key metabolic biomarkers, i.e. leptin, insulin, CRP, insulin resistance (HOMA) in the phase III BWEL study (n=3,181), elegantly presented at SABCS 2024.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 17, 2024, 23:14
Dec 17, 2024, 23:14
Dec 17, 2024, 23:14
Dec 17, 2024, 23:14
Dec 17, 2024, 23:14
Dec 17, 2024, 23:14
Dec 17, 2024, 23:14